Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: GX-I7|DRUG: Pembrolizumab|DRUG: cyclophosphamide
Sponsor: Genexine, Inc.
Collaborators: Merck Sharp & Dohme LLC